What the research actually shows
A series of large observational studies published in 2025-2026 have consistently found that people with type 2 diabetes treated with GLP-1 receptor agonists show significantly lower rates of Alzheimer's disease and other dementias compared to those treated with other glucose-lowering medications.
The most-cited study — a retrospective cohort analysis of over 1.6 million patients — found semaglutide users had a 40-70% lower incidence of new Alzheimer's diagnoses over a 3-year follow-up period. Liraglutide showed similar but somewhat smaller effects.
"These findings are striking, but we must be clear — observational data cannot prove causation. People who receive GLP-1 drugs may differ from comparison groups in important ways we cannot fully control for." — Lead author, University of Oxford, 2025
How GLP-1 drugs may protect the brain
GLP-1 receptors are widely expressed in the central nervous system, particularly in the hippocampus, cortex, and hypothalamus — regions critical to memory and cognition. Several mechanisms have been proposed:
- Neuroinflammation reduction: GLP-1 agonists suppress microglial activation and pro-inflammatory cytokine production, both implicated in Alzheimer's pathology.
- Improved cerebral insulin signalling: Alzheimer's has been described as "type 3 diabetes" — a state of brain insulin resistance. GLP-1 drugs enhance neuronal insulin sensitivity.
- Amyloid and tau modulation: Animal and early human studies suggest reduced amyloid-beta plaque formation and tau phosphorylation with GLP-1 treatment.
- Neurogenesis promotion: GLP-1 appears to promote hippocampal neurogenesis and synaptic plasticity in preclinical models.
- Cardiovascular risk reduction: GLP-1 drugs significantly reduce stroke and cardiovascular events — both established risk factors for vascular dementia.
The critical caveats every patient should know
The headlines have been dramatic. The reality is more nuanced:
- No drug is approved for dementia prevention. These are off-label observations, not approved indications.
- The studies were in diabetic populations. Whether the same effects occur in people without diabetes is unknown.
- Randomised controlled trial data is pending. The EVOKE trial and HEAL trial are expected to report by 2027. These are the studies that will — or will not — confirm the observational findings.
- Significant side effects exist. Nausea, vomiting, gastroparesis risk, and rare cases of pancreatitis require careful patient selection and monitoring.
- Supply remains constrained. Prescribing for unapproved indications where supply is limited raises ethical and access concerns.
Current eligibility criteria for GLP-1 treatment
In the UK and most international guidelines, GLP-1 receptor agonists are currently approved for:
| Indication | Criteria | Example drugs |
|---|---|---|
| Type 2 diabetes | Inadequate glycaemic control on other agents | Semaglutide, liraglutide, dulaglutide |
| Obesity | BMI ≥30, or ≥27 with comorbidity | Semaglutide (Wegovy), liraglutide (Saxenda) |
| Cardiovascular risk reduction | Established CVD with T2DM | Semaglutide, liraglutide |
Dementia prevention is not a current approved indication in any country. Clinicians prescribing for this purpose would be doing so off-label with significant uncertainty about benefit-risk balance.
What this means for your clinical practice
For primary care clinicians and endocrinologists, the immediate practical message is straightforward: if a patient with type 2 diabetes or obesity meets criteria for GLP-1 treatment, the emerging neurological data is one more reason to consider it — not to withhold it while waiting for RCT confirmation.
For patients asking about GLP-1 drugs specifically for dementia prevention: be honest that the evidence is promising but preliminary. Lifestyle modification — exercise, sleep, Mediterranean diet, blood pressure control — has substantially stronger evidence for dementia risk reduction than any drug currently available.
Use our BMI Calculator to assess eligibility thresholds, and screen for comorbid depression — which is both a dementia risk factor and commonly undertreated in patients on GLP-1 therapy — with our PHQ-9 Depression Screening tool.
Frequently Asked Questions
References
- Wang W, et al. "Semaglutide and risk of Alzheimer's disease." Alzheimer's & Dementia. 2025.
- Atri A, et al. "GLP-1 receptor agonists and cognitive outcomes: systematic review." NEJM Evidence. 2026.
- Holscher C. "GLP-1 receptor agonists: A novel treatment approach in Alzheimer's disease." Brain Research. 2020;1725:146490.
- NICE. Semaglutide for managing overweight and obesity (TA875). NICE, 2023.